Fig. 3From: Add-on neurological benefits of antiviral therapy in HCV patients with chronic kidney disease — a nationwide cohort study a All-cause mortality survival curves in the “treated ≥16 weeks” and incompletely treated (<16 weeks) and untreated cohorts; b incidence density of hemorrhagic stroke in the three cohorts based on the duration of therapyBack to article page